

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.111

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorials

- 949** Musculoskeletal disorders and the Global Burden of Disease Study
K Storchheim, J-A Zwart
- 951** Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?
C Orr, D J Veale

Viewpoint

- 954** Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system
I A M van den Oever, N Sattar, M T Nurmohamed

Recommendation

- 958** Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
R F van Vollenhoven, M Mosca, G Bertias, D Isenberg, A Kuhn, K Lerstrom, M Aringer, H Bootsma, D Boumpas, I N Bruce, R Cervera, A Clarke, N Costedoat-Chalumeau, L Czizjak, R Derksen, T Dörner, C Gordon, W Graninger, F Houssiau, M Inanc, S Jacobsen, D Jayne, A Jedryka-Goral, A Levitsky, R Levy, X Mariette, E Morand, S Navarra, I Neumann, A Rahman, J Rovenský, J Smolen, C Vasconcelos, A Voskuyl, A Voss, H Zakharova, A Zoma, M Schneider

Clinical and epidemiological research

- 968** The global burden of low back pain: estimates from the Global Burden of Disease 2010 study
D Hoy, L March, P Brooks, F Blyth, A Woolf, C Bain, G Williams, E Smith, T Vos, J Barendregt, C Murray, R Burstein, R Buchbinder
- 975** The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study
T Driscoll, G Jackelyn, J Orchard, E Passmore, T Vos, G Freedman, S Lim, L Punnett
- 982** The global burden of musculoskeletal conditions for 2010: an overview of methods
D G Hoy, E Smith, M Cross, L Sanchez-Riera, R Buchbinder, F M Blyth, P Brooks, A D Woolf, R H Osborne, M Fransen, T Driscoll, T Vos, J D Blore, C Murray, N Johns, M Naghavi, E Carnahan, L M March
- 990** Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
C Ritchlin, P Rahman, A Kavanaugh, I B McInnes, L Puig, S Li, Y Wang, Y-K Shen, M K Doyle, A M Mendelsohn, A B Gottlieb, on behalf of the PSUMMIT 2 Study Group
- 1000** Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
A Kavanaugh, C Ritchlin, P Rahman, L Puig, A B Gottlieb, S Li, Y Wang, L Noonan, C Brodmerkel, M Song, A M Mendelsohn, I B McInnes, on behalf of the PSUMMIT-1 and 2 Study Groups
- 1007** Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis
L Eder, A Thavaneswaran, V Chandran, D D Gladman
- 1012** A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative
L Gossec, M de Wit, U Kiltz, J Braun, U Kalyoncu, R Scivo, M Maccarone, L Carton, K Otsa, I Sooäär, T Heiberg, H Bertheussen, J D Cañete, A S Lombarte, A Balanescu, A Dinte, K de Vlam, J S Smolen, T Stamm, D Niedermayer, G Békés, D Veale, P Helliwell, A Parkinson, T Luger, T K Kvien, On behalf of the EULAR PsAID Taskforce
- 1020** Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
A Kavanaugh, P J Mease, J J Gomez-Reino, A O Adebajo, J Wollenhaupt, D D Gladman, E Lespessailles, S Hall, M Hochfeld, C C Hu, D Hough, R M Stevens, G Schett
- 1027** A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial
J L Nam, E Villeneuve, E M A Hensor, R J Wakefield, P G Conaghan, M J Green, A Gough, M Quinn, R Reece, S R Cox, M H Buch, D M van der Heijde, P Emery
- 1037** Use of strontium ranelate and risk of acute coronary syndrome: cohort study
H Svanström, B Pasternak, A Hviid
- 1044** Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial
N Dalbeth, O Aati, G D Gamble, A Home, M E House, M Roger, A J Doyle, A Chhana, F M McQueen, I R Reid
- 1052** MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome
N I Maria, Z Brčić, M Waris, C G van Helden-Meeuwssen, K Heezen, J P van de Merwe, P L van Daele, V A S H Dalm, H A Drexhage, M A Versnel

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme.
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1060** The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis
T R Cottrell, R A Wise, F M Wigley, F Boin
- 1067** Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited
V Navarro-Compán, D van der Heijde, H A Ahmad, C G Miller, R Wolterbeek, R Landewé
- 1071** A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks
D den Uyl, M ter Wee, M Boers, P Kerstens, A Voskuyl, M Nurmohamed, H Raterman, D van Schaardenburg, N van Dillen, B Dijkmans, W Lems
- 1079** High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis
X Baraliakos, N Baerlecken, T Witte, F Heldmann, J Braun
- 1083** Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis
C Malattia, M B Damasio, A Madeo, A Pistorio, A Providenti, S Pederzoli, S Viola, A Buoncompagni, C Mattiuz, A Beltramo, A Consolaro, A Ravelli, N Ruperto, P Picco, G M Magnano, A Martini
- 1091** The risk of atrial fibrillation in patients with rheumatoid arthritis
S C Kim, J Liu, D H Solomon
- 1096** Thyroxin substitution and the risk of developing rheumatoid arthritis; results from the Swedish population-based EIRA study
C Bengtsson, L Padyukov, H Källberg, S Saevarsdottir
- 1101** Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis
B Herz, A Albrecht, M Englbrecht, G H Welsch, M Uder, N Renner, P Schlechtweg, D Paul, L Lauer, K Engelke, R Janke, J Rech, G Schett, S Finzel
- 1107** The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
J Braun, X Baraliakos, K-G A Hermann, A Deodhar, D van der Heijde, R Inman, A Beutler, Y Zhou, S Xu, B Hsu
- 1114** Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
G Horneff, R Burgos-Vargas, T Constantin, I Foeldvari, J Vojinovic, V G Chasnyk, J Dehoorne, V Panaviene, G Susic, V Stanevica, K Kobusinska, Z Zuber, R Mouy, I Rumba-Rozenfelde, L Breda, P Dolezalova, C Job-Deslandre, N Wulffraat, D Alvarez, C Zang, J Wajdula, D Woodworth, B Vlahos, A Martini, N Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO)
- 1123** Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
T W Jensen, M S Hansen, K Horslev-Petersen, L Hylidstrup, B Abrahamsen, B Langdahl, B Zerahn, J Pødenphant, K Stengaard-Petersen, P Junker, M Østergaard, T Lottenburger, T Ellingsen, L S Andersen, I Hansen, H Skjeldt, J K Pedersen, U B Lauridsen, A J Svendsen, U Tarp, H Lindegaard, A G Jurik, A Vestergaard, M L Hetland, the Cimesra study group
- 1130** Postoperative effects of neuromuscular exercise prior to hip or knee arthroplasty: a randomised controlled trial
A Villadsen, S Overgaard, A Holsgaard-Larsen, R Christensen, E M Roos
- 1138** A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
S Garcés, M Antunes, E Benito-Garcia, J C da Silva, L Aarden, J Demengeot
- 1144** Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
B Parker, A Al-Husain, P Pemberton, A P Yates, P Ho, R Gorodkin, L S Teh, M Y Alexander, I N Bruce
- 1151** Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis
Y Liang, Z Yang, B Qin, R Zhong
- 1157** Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers
M N D Di Minno, R Peluso, S Iervolino, A Russolillo, R Lupoli, R Scarpa, on behalf of the CaRRDs Study Group
- 1163** A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis
D P C de Rooy, A Zhernakova, R Tsonaka, A Willemze, B A S Kurreeman, G Trynka, L van Toorn, R E M Toes, T W J Huizinga, J J Houwing-Duistermaat, P K Gregersen, A H M van der Helm-van Mil
- 1170** Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls
K P Liao, D Diogo, J Cui, T Cai, Y Okada, V S Gainer, S N Murphy, N Gupta, D Mirel, A N Ananthakrishnan, P Szolovits, S Y Shaw, S Raychaudhuri, S Churchill, I Kohane, E W Karlson, R M Plenge
- 1176** A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients
D Erkan, R Willis, V L Murthy, G Basra, JoAnn Vega, P Ruiz-Limón, A L Carrera, E Papalardo, L A Martínez-Martínez, E B González, S S Pierangeli
- 1181** Laser speckle contrast analysis: a new method to evaluate peripheral blood perfusion in systemic sclerosis patients
B Ruaro, A Sulli, E Alessandri, C Pizzorni, G Ferrari, M Cutolo
- 1186** Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort
L Van Praet, L Jans, P Carron, P Jacques, E Glorieux, R Colman, H Cypers, H Mielants, M De Vos, C Cuvelier, F Van den Bosch, D Elewaut
- 1190** Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study
P Macchioni, L Boiardi, M Catanoso, G Pazzola, C Salvarani

- 1194** Hip replacement surgery in patients with ankylosing spondylitis

T W Nystad, O Furnes, L I Havelin, A K Skredderstuen, S A Lie, B-T S Fevang

- 1198** Genetic variation in *VTCN1* (B7-H4) is associated with course of disease in juvenile idiopathic arthritis

H M Albers, T H C M Reinards, D M C Brinkman, S S M Kamphuis, M A J van Rossum, E P A H Hoppenreijns, H J Girschick, C Wouters, R K Saurenmann, E Bakker, W Verduijn, P Slagboom, T W J Huizinga, R E M Toes, J J Houwing-Duistermaat, R ten Cate, M W Schilham

Basic and translational research

- 1202** Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment

R J Mathews, J I Robinson, M Battellino, C Wong, J C Taylor, *Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate* (BRAGGSS), S Eyre, S M Churchman, A G Wilson, J D Isaacs, K Hyrich, A Barton, D Plant, S Savic, G P Cook, P Sarzi-Putini, P Emery, J H Barrett, A W Morgan, M F McDermott

- 1211** Autoantibodies against CD74 in spondyloarthritis

N T Baerlecken, S Nothdorff, G H Stummvoll, J Sieper, M Rudwaleit, S Reuter, T Mathias, R E Schmidt, T Witte

- 1215** Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- β signalling to prevent fibrosis

M Tomcik, P Zerr, J Pitkowski, K Palumbo-Zerr, J Avouac, O Distler, R Becvar, L Senolt, G Schett, J H Distler

- 1223** Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF- α production by interaction with its soluble E-cadherin ligand in chronically inflamed joints

L Melis, L Van Praet, H Pircher, K Venken, D Elewaut

- 1232** The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis

C Dees, I Schlottmann, R Funke, A Distler, K Palumbo-Zerr, P Zerr, N-Y Lin, C Beyer, O Distler, G Schett, J H W Distler

- 1240** Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women

H-S Lee, T Kim, S Y Bang, Y J Na, I Kim, K Kim, J-H Kim, Y-J Chung, H D Shin, Y M Kang, S-C Shim, C-H Suh, Y-B Park, J-S Kim, C Kang, S-C Bae

- 1246** The fibrin-derived citrullinated peptide β 60–74Cit_{60,72,74} bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies

M Cornillet, M Sebbag, E Verrouil, A Magyar, F Babos, A Ruyssen-Witrand, F Hudecz, A Cantagrel, G Serre, L Nogueira

- 1253** Genetic associations to germinal centre formation in primary Sjögren's syndrome

T R Rekesten, S J A Johnsen, M V Jonsson, R Omdal, J G Brun, E Theander, P Eriksson, M Wahren-Herlenius, R Jonsson, G Nordmark

- 1259** Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome

A Awada, C Nicaise, S Ena, L Schandéné, J Rasschaert, I Popescu, V Gängi, M S Soyfo

- 1264** Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability

A Distler, V Lang, T Del Vecchio, J Huang, Y Zhang, C Beyer, N-Y Lin, K Palumbo-Zerr, O Distler, G Schett, J H W Distler

- 1269** Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study



Z Zhu, Y Yin, K Zheng, F Li, X Chen, F Zhang, X Zhang

Letters

- 1273** An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis

G P R Clunie, A Ginawi, P O'Conner, P W Bearcroft, S J Garber, S Bhagat, A Grainger, J S H Gaston

- 1274** Hydrocortisone directly promotes cholesterol accumulation in macrophages

D Greco, E Favari, M P Adorni, F Zimetti, R Gatti, F Bernini, N Ronda

- 1276** Levels of soluble osteoclast-associated receptor (sOSCAR) in rheumatoid arthritis: link to disease severity and cardiovascular risk

N Ndongo-Thiam, G de Sallmard, J Kastrup, P Miossec

- 1277** Antibodies against *Porphyromonas gingivalis* in seropositive arthralgia patients do not predict development of rheumatoid arthritis

M de Smit, L A van de Stadt, K M J Janssen, B Doornbos-van der Meer, A Vissink, A J van Winkelhoff, E Brouwer, J Westra, D van Schaardenburg

- 1279** Fluorescence optical imaging as a novel technique for the visualisation of inflammation in patients with systemic sclerosis with Raynaud's phenomenon: a pilot study

A Pfeil, K F Drummer, P Oelzner, J Bötcher, C Jung, G Wolf

Electronic pages

- e31** Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Register)

F Iannone, G Ferraccioli, E Gremese, G Lapadula, for the Gruppo Italiano di Studio sulle Early Artriti (GISEA)

- e32** Response to: 'Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Register)' by Iannone *et al*

M Neovius, J Askeling

- e33** Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital *et al*

M Bredemeier

- e34** Response to Dr Bredemeier's letter

E M Vital, S Dass, M H Buch, A C Rawstron, P Emery